Cryo-Cell International (CCEL)
Market Price (6/26/2026): $3.74 | Market Cap: $30.1 MilSector: Health Care | Industry: Health Care Facilities
Cryo-Cell International (CCEL)
Market Price (6/26/2026): $3.74Market Cap: $30.1 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16% Attractive yieldDividend Yield is 3.9%, FCF Yield is 16% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Cellular & Regenerative Medicine, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -85%, 3Y Excs Rtn is -96% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.6%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.4%, Rev Chg QQuarterly Revenue Change % is -3.6% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.8% Key risksCCEL key risks include the uncertain success of its strategic diversification, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16% |
| Attractive yieldDividend Yield is 3.9%, FCF Yield is 16% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Cellular & Regenerative Medicine, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -85%, 3Y Excs Rtn is -96% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.6%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.4%, Rev Chg QQuarterly Revenue Change % is -3.6% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.8% |
| Key risksCCEL key risks include the uncertain success of its strategic diversification, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Cryo-Cell International (CCEL) stock has gained about 15% since 2/28/2026 because of the following key factors:
1. Acceptance of NYSE American Compliance Plan mitigated delisting concerns. On March 12, 2026, Cryo-Cell International received a notice from NYSE American indicating non-compliance with listing standards due to a stockholders' deficit and net losses in recent fiscal years. However, on May 8, 2026, NYSE Regulation accepted the company's plan to regain compliance, granting a period through September 9, 2027. This acceptance likely reduced investor uncertainty regarding the stock's continued listing.
2. Fiscal Q1 2026 earnings showed a return to profitability. The company reported earnings per share (EPS) of $0.01 for its fiscal first quarter ended February 28, 2026, with these results released on April 14, 2026. This positive EPS for fiscal Q1 2026 followed a net loss of $2.4 million for the full fiscal year ended November 30, 2025. The shift to profitability in the first quarter of fiscal 2026 provided a positive outlook for investors.
Show more
Cryo-Cell International (CCEL) stock has gained about 15% since 2/28/2026 because of the following key factors:
1. Acceptance of NYSE American Compliance Plan mitigated delisting concerns. On March 12, 2026, Cryo-Cell International received a notice from NYSE American indicating non-compliance with listing standards due to a stockholders' deficit and net losses in recent fiscal years. However, on May 8, 2026, NYSE Regulation accepted the company's plan to regain compliance, granting a period through September 9, 2027. This acceptance likely reduced investor uncertainty regarding the stock's continued listing.
2. Fiscal Q1 2026 earnings showed a return to profitability. The company reported earnings per share (EPS) of $0.01 for its fiscal first quarter ended February 28, 2026, with these results released on April 14, 2026. This positive EPS for fiscal Q1 2026 followed a net loss of $2.4 million for the full fiscal year ended November 30, 2025. The shift to profitability in the first quarter of fiscal 2026 provided a positive outlook for investors.
3. Receipt of FACT Re-accreditation reinforced quality and industry standing. On April 28, 2026, Cryo-Cell International announced it had received FACT Re-accreditation, which signifies adherence to stringent quality standards and establishes the company's longest independently validated quality track record among U.S. private cord blood banks. This achievement underscored the company's commitment to quality and leadership within its specialized industry.
Show less
Stock Movement Drivers
Fundamental Drivers
The 12.9% change in CCEL stock from 2/28/2026 to 6/25/2026 was primarily driven by a 14.0% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 6252026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.40 | 3.84 | 12.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 31 | -0.9% |
| P/S Multiple | 0.9 | 1.0 | 14.0% |
| Shares Outstanding (Mil) | 8 | 8 | 0.0% |
| Cumulative Contribution | 12.9% |
Market Drivers
2/28/2026 to 6/25/2026| Return | Correlation | |
|---|---|---|
| CCEL | 12.9% | |
| Market (SPY) | 7.3% | 6.4% |
| Sector (XLV) | -2.5% | -1.5% |
Fundamental Drivers
The -10.7% change in CCEL stock from 11/30/2025 to 6/25/2026 was primarily driven by a -9.4% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6252026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.30 | 3.84 | -10.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 31 | -1.5% |
| P/S Multiple | 1.1 | 1.0 | -9.4% |
| Shares Outstanding (Mil) | 8 | 8 | 0.0% |
| Cumulative Contribution | -10.7% |
Market Drivers
11/30/2025 to 6/25/2026| Return | Correlation | |
|---|---|---|
| CCEL | -10.7% | |
| Market (SPY) | 8.1% | 5.3% |
| Sector (XLV) | -0.5% | -6.7% |
Fundamental Drivers
The -25.0% change in CCEL stock from 5/31/2025 to 6/25/2026 was primarily driven by a -23.3% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6252026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.12 | 3.84 | -25.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 31 | -2.6% |
| P/S Multiple | 1.3 | 1.0 | -23.3% |
| Shares Outstanding (Mil) | 8 | 8 | 0.3% |
| Cumulative Contribution | -25.0% |
Market Drivers
5/31/2025 to 6/25/2026| Return | Correlation | |
|---|---|---|
| CCEL | -25.0% | |
| Market (SPY) | 26.0% | 8.4% |
| Sector (XLV) | 19.4% | 6.8% |
Fundamental Drivers
The -13.3% change in CCEL stock from 5/31/2023 to 6/25/2026 was primarily driven by a -18.3% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6252026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.43 | 3.84 | -13.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 31 | 31 | 1.2% |
| P/S Multiple | 1.2 | 1.0 | -18.3% |
| Shares Outstanding (Mil) | 8 | 8 | 4.8% |
| Cumulative Contribution | -13.3% |
Market Drivers
5/31/2023 to 6/25/2026| Return | Correlation | |
|---|---|---|
| CCEL | -13.3% | |
| Market (SPY) | 82.6% | 5.9% |
| Sector (XLV) | 28.0% | 3.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CCEL Return | 84% | -64% | 36% | 33% | -51% | 10% | -34% |
| Peers Return | 6% | -42% | -9% | -0% | -14% | 14% | -45% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| CCEL Win Rate | 25% | 8% | 42% | 42% | 33% | 50% | |
| Peers Win Rate | 52% | 42% | 44% | 50% | 46% | 42% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CCEL Max Drawdown | -21% | -65% | -40% | -38% | -58% | -20% | |
| Peers Max Drawdown | -49% | -61% | -49% | -40% | -47% | -34% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: RVTY, CYRX, VCEL, PLUR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/25/2026 (YTD)
How Low Can It Go
| Event | CCEL | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -16.9% | -7.8% |
| % Gain to Breakeven | 20.3% | 8.5% |
| Time to Breakeven | 80 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.8% | -9.5% |
| % Gain to Breakeven | 46.5% | 10.5% |
| Time to Breakeven | 16 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -24.0% | -6.7% |
| % Gain to Breakeven | 31.6% | 7.1% |
| Time to Breakeven | 27 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -21.4% | -33.7% |
| % Gain to Breakeven | 27.3% | 50.9% |
| Time to Breakeven | 531 days | 140 days |
| 2013 Taper Tantrum | ||
| % Loss | -18.2% | -0.2% |
| % Gain to Breakeven | 22.2% | 0.2% |
| Time to Breakeven | 157 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -34.6% | -17.9% |
| % Gain to Breakeven | 52.9% | 21.8% |
| Time to Breakeven | 947 days | 123 days |
In The Past
Cryo-Cell International's stock fell -16.9% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 20.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CCEL | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.8% | -9.5% |
| % Gain to Breakeven | 46.5% | 10.5% |
| Time to Breakeven | 16 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -24.0% | -6.7% |
| % Gain to Breakeven | 31.6% | 7.1% |
| Time to Breakeven | 27 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -21.4% | -33.7% |
| % Gain to Breakeven | 27.3% | 50.9% |
| Time to Breakeven | 531 days | 140 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -34.6% | -17.9% |
| % Gain to Breakeven | 52.9% | 21.8% |
| Time to Breakeven | 947 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -31.2% | -15.4% |
| % Gain to Breakeven | 45.4% | 18.2% |
| Time to Breakeven | 2 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -47.4% | -53.4% |
| % Gain to Breakeven | 90.0% | 114.4% |
| Time to Breakeven | 153 days | 1085 days |
In The Past
Cryo-Cell International's stock fell -16.9% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 20.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Cryo-Cell International (CCEL)
Cryo-Cell International (CCEL) specializes in the cellular processing and cryogenic storage of umbilical cord blood stem cells, primarily for private family use. The company offers a vital service that allows expectant parents to collect and preserve these stem cells at birth, providing a biological resource for potential future medical applications. With a significant global presence, Cryo-Cell maintains a vast repository, currently storing approximately 500,000 cord blood and cord tissue stem cell units worldwide.
Expanding beyond cord blood, Cryo-Cell International also provides a cord tissue service, which involves storing a section of the umbilical cord itself. This tissue is a rich source of mesenchymal stem cells, highly valued in regenerative medicine for their potential in treating a range of conditions, including heart and kidney disease, ALS, wound healing, and various auto-immune diseases. The company further differentiates itself by manufacturing and selling its proprietary PrepaCyte CB processing system, a specialized technology utilized for efficient processing of umbilical cord blood stem cells.
Cryo-Cell International markets its comprehensive stem cell preservation services directly to expectant parents, highlighting the long-term health and wellness benefits for their families. To broaden its reach and educate potential clients, the company also distributes informational materials and collaborates with a network of healthcare professionals, including obstetricians, pediatricians, childbirth educators, and certified nurse-midwives, who in turn inform their patients about these valuable services.
AI Analysis | Feedback
Here are 1-2 brief analogies for Cryo-Cell International (CCEL):
- It's like Fidelity Investments, but instead of managing your child's financial future, they preserve their stem cells for future health.
- It's like Iron Mountain, but for human stem cells, providing long-term cryogenic storage of umbilical cord blood and tissue.
AI Analysis | Feedback
- Cord Blood Banking: A service focused on the collection, processing, and cryogenic storage of umbilical cord blood stem cells for potential future family use.
- Cord Tissue Banking: A service for storing a section of the umbilical cord tissue, a source of mesenchymal stem cells used in regenerative medicine.
- PrepaCyte CB processing system: A proprietary technology manufactured and sold by the company, used for processing umbilical cord blood stem cells.
AI Analysis | Feedback
Cryo-Cell International (CCEL) primarily serves individuals, specifically expectant parents and families, for its core cord blood and cord tissue stem cell storage services. However, it also serves other categories related to its business model and product offerings.
The major customer categories that Cryo-Cell International serves are:
- Expectant Parents and Families: These are the primary direct consumers who purchase the cord blood and cord tissue stem cell preservation and cryogenic storage services for their family's potential future medical use in regenerative medicine or other therapeutic applications.
- Healthcare Professionals and Childbirth Educators: While not direct paying customers for the storage services, this group includes obstetricians, pediatricians, certified nurse-midwives, and childbirth educators. Cryo-Cell International markets to and distributes information through these professionals, who serve as crucial informational channels and influencers for expectant parents considering stem cell preservation.
- Other Cellular Processing Facilities, Research Institutions, and Cord Blood Banks: These entities represent business-to-business customers who purchase the PrepaCyte CB processing system, a proprietary technology manufactured and sold by Cryo-Cell International for processing umbilical cord blood stem cells.
AI Analysis | Feedback
AI Analysis | Feedback
David I. Portnoy Co-Chief Executive Officer
Mr. Portnoy has served as Chairman of the Board and Co-Chief Executive Officer of Cryo-Cell International since August 2011. Since 2002, he has also served as Chairman of the Board of Directors of Partner Community, Inc., which facilitates B2B integrations for telecommunication service providers. His venture capital company led early-stage investment rounds in Waves Audio Ltd, a leading developer of audio plugins and signal processors. Mr. Portnoy has been engaged in managing his personal investments since April 1997. He graduated Magna Cum Laude from The Wharton School of Finance at the University of Pennsylvania in 1984.
Mark L. Portnoy Co-Chief Executive Officer
Mr. Portnoy has served as a Director and Co-Chief Executive Officer of Cryo-Cell International since August 2011. He has been instrumental in expanding the company's core business units, including leading the establishment of a national sales force in 2012, the adoption and acquisition of exclusive worldwide rights to the PrepaCyte-CB processing system, and the purchase of Cord:Use Cord Blood Bank. Since 2002 and 2007, he has also served on the boards of directors of Partner-Community, Inc. and uTIPu Inc., respectively.
Jill Taymans Chief Financial Officer
Ms. Taymans has served as Cryo-Cell International's Chief Financial Officer since 1998. Prior to joining the company, she served for three years as Controller for a telecommunications company. Ms. Taymans has over 30 years of experience as an accountant in both the public and private sectors. She graduated from the University of Maryland in 1991 with a BS in Accounting.
Oleg Mikulinsky Chief Information Officer
Mr. Mikulinsky has served as Cryo-Cell International's Chief Information Officer since March 2012. He is a software technologist and serial entrepreneur, having been a founding member of several software enterprises. He previously served as Chief Technology Officer of Partner-Community, Inc. and Chief Technology Officer at uTIPu Inc. from 2007 to 2009. Mr. Mikulinsky also served as the Director of Enterprise Architecture at WebLayers, Inc.
Joanne Kurtzberg, M.D. Medical Director
Dr. Kurtzberg is the Medical Director of Cryo-Cell International. She is recognized as a pioneer in the cord blood field, having performed the first unrelated cord blood stem cell transplant in 1993. Dr. Kurtzberg is an internationally renowned expert in pediatric hematology-oncology, pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation, and the novel application of cord blood in cellular therapy and regenerative medicine. She is the Director of the Marcus Center for Cellular Cures at the Duke University School of Medicine and is President of the Cord Blood Association.
AI Analysis | Feedback
The key risks to Cryo-Cell International's business include the risk of NYSE American delisting, uncertainty from the Duke arbitration, and reliance on the evolving landscape of stem cell therapies amidst intense market competition.
The most significant risk is the potential for **NYSE American delisting and associated financial instability**. Cryo-Cell International has received a notice from NYSE American indicating non-compliance with continued listing standards, specifically due to a stockholders' deficit and net losses in recent fiscal years. Failure to regain compliance could lead to the delisting of its common stock, which would likely depress the stock price, severely limit liquidity, and restrict the company's ability to raise additional capital.
Another major risk is the **uncertainty and potential negative impact stemming from the Duke arbitration**. An ongoing dispute with Duke University over the Duke License Agreement introduces significant uncertainty, with potential negative impacts on Cryo-Cell International's business and financial position. The outcome of this arbitration is unpredictable, and there is a risk of not recouping damages or investments related to the agreement. This dispute has also reportedly halted investments in related activities and delayed the opening of the Cryo-Cell Institute for Cellular Therapies.
Finally, Cryo-Cell International faces risks associated with its **reliance on the evolving landscape of stem cell therapies and intense market competition**. The success and long-term viability of the company's core service—the collection and preservation of umbilical cord blood and tissue stem cells—are heavily dependent on the widespread market acceptance and continued advancements in regenerative medicine and stem cell therapeutic applications. The stem cell preservation market is increasingly competitive, with approximately 25 other national private cord blood banks, some potentially possessing greater financial resources, which can lead to pricing pressures and challenges in customer acquisition.
AI Analysis | Feedback
The clear emerging threat to Cryo-Cell International is the advancement and increasing therapeutic utility of induced pluripotent stem cell (iPSC) technology.
iPSC technology allows adult somatic cells (e.g., skin cells) to be reprogrammed into a pluripotent state, meaning they can differentiate into any cell type in the body. As this technology matures and becomes more readily available, efficient, and cost-effective, it could significantly diminish the value proposition of banking umbilical cord blood and tissue at birth for future therapeutic use. If individuals can generate patient-specific pluripotent stem cells from their own adult cells at any point in their lives, the need for long-term cryopreservation of perinatal stem cells for "family use" may decrease, thereby threatening Cryo-Cell International's core business model.
AI Analysis | Feedback
Umbilical Cord Blood Stem Cells and Cord Tissue Preservation (Family Use)
The global addressable market for cord blood banking services, which encompasses both umbilical cord blood and cord tissue storage for family use, was estimated at US$33.9 billion in 2023. This market is projected to grow to US$65.36 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 6.15% from 2024 to 2034. For the U.S. region, the cord blood banking services market was valued at USD 6.83 billion in 2022. It is expected to grow at a CAGR of 11.56% from 2023 to 2030, reaching an estimated USD 16.59 billion by 2030. North America, overall, held a significant share of the global cord blood banking services market, accounting for 42.5% in 2023 and 42% in 2024.PrepaCyte CB Processing System
nullAI Analysis | Feedback
AI Analysis | Feedback
Share Repurchases
- Cryo-Cell International repurchased $169,502 of its common stock in fiscal year 2025.
Share Issuance
- Information regarding significant share issuances by the company for cash over the last 3-5 years was not readily available in the provided search results.
Inbound Investments
- Cryo-Cell International entered into a Credit Agreement with Susser Bank, which provides for a revolving credit facility and a term loan facility.
Outbound Investments
- In February 2021, Cryo-Cell entered into an exclusive, collaborative license agreement with Duke University, granting the company rights to intellectual property, proprietary processes, and regulatory/clinical data related to cord blood and cord tissue.
- The company acquired assets from Cord:Use Cord Blood Bank, Inc., which enhanced its public cord blood inventory.
- Cryo-Cell purchased a 56,000 square-foot facility in Durham, North Carolina, to expand its cryopreservation and cold storage business.
Capital Expenditures
- The company acquired a 56,000 square-foot facility in Durham, North Carolina, to expand its cryopreservation and cold storage capabilities.
- Planned capital expenditures for the Cryo-Cell Institute for Cellular Therapies, which aimed to support biopharmaceutical manufacturing and clinic operations, have been halted due to a dispute with Duke University.
- Cryo-Cell anticipates that its current cash, marketable securities, and operating cash flows will cover known needs for the next 12 months, but additional capital may be required for future clinical trials and biopharmaceutical manufacturing depending on the outcome of the Duke License Agreement arbitration.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Cryo-Cell International Earnings Notes | 12/16/2025 | |
| Can Cryo-Cell International Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 15.88 |
| Mkt Cap | 0.8 |
| Rev LTM | 183 |
| Op Inc LTM | 5 |
| FCF LTM | 5 |
| FCF 3Y Avg | 3 |
| CFO LTM | 5 |
| CFO 3Y Avg | 6 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.8% |
| Rev Chg 3Y Avg | 0.4% |
| Rev Chg Q | 7.0% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Inc Chg LTM | 13.1% |
| Op Inc Chg 3Y Avg | 2.5% |
| Op Mgn LTM | 5.4% |
| Op Mgn 3Y Avg | 0.8% |
| QoQ Delta Op Mgn LTM | -0.6% |
| CFO/Rev LTM | 16.5% |
| CFO/Rev 3Y Avg | 16.0% |
| FCF/Rev LTM | 15.8% |
| FCF/Rev 3Y Avg | 4.8% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Umbilical cord blood and cord tissue stem cell service | 31 | 32 | 31 | 30 | 28 |
| Public cord blood banking | 0 | 0 | 0 | 0 | 0 |
| PrepaCyte Cord Blood (CB) | 0 | 0 | 0 | 0 | 0 |
| Total | 32 | 32 | 31 | 30 | 29 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Umbilical cord blood and cord tissue stem cell service | 5 | 4 | -8 | 5 | 6 |
| PrepaCyte Cord Blood (CB) | 0 | -0 | 0 | -0 | -0 |
| Public cord blood banking | -5 | -1 | -4 | -1 | -2 |
| Total | 0 | 3 | -12 | 4 | 4 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Umbilical cord blood and cord tissue stem cell service | 61 | 59 | 55 | 55 | 50 |
| Public cord blood banking | 1 | 5 | 6 | 10 | 10 |
| PrepaCyte Cord Blood (CB) | 0 | 0 | 0 | 0 | 0 |
| Total | 62 | 65 | 61 | 65 | 61 |
Price Behavior
| Market Price | $3.84 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -29.3% | |
| 50 Days | 200 Days | |
| DMA Price | $3.58 | $3.78 |
| DMA Trend | down | up |
| Distance from DMA | 7.2% | 1.7% |
| 3M | 1YR | |
| Volatility | 75.6% | 58.7% |
| Downside Capture | 88.68 | 59.03 |
| Upside Capture | 107.07 | 11.43 |
| Correlation (SPY) | 7.7% | 7.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.02 | 1.67 | 0.35 | 0.30 | 0.41 | 0.24 |
| Up Beta | 0.55 | 2.17 | 2.01 | 1.70 | 1.70 | 0.22 |
| Down Beta | 0.23 | 1.03 | -1.80 | -0.79 | -0.67 | 0.24 |
| Up Capture | 63% | 49% | 16% | -16% | -0% | 4% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 9 | 21 | 29 | 56 | 109 | 350 |
| Down Capture | 229% | 318% | 36% | 52% | 77% | 60% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 10 | 19 | 30 | 62 | 130 | 380 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCEL | |
|---|---|---|---|---|
| CCEL | -24.7% | 58.4% | -0.27 | - |
| Sector ETF (XLV) | 17.9% | 15.1% | 0.88 | 5.6% |
| Equity (SPY) | 22.1% | 12.4% | 1.33 | 6.9% |
| Gold (GLD) | 20.8% | 27.7% | 0.67 | 1.5% |
| Commodities (DBC) | 23.3% | 18.5% | 0.99 | 3.0% |
| Real Estate (VNQ) | 11.6% | 13.8% | 0.55 | 2.0% |
| Bitcoin (BTCUSD) | -42.9% | 42.5% | -1.20 | 0.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCEL | |
|---|---|---|---|---|
| CCEL | -18.2% | 66.1% | -0.06 | - |
| Sector ETF (XLV) | 6.2% | 14.8% | 0.23 | 1.5% |
| Equity (SPY) | 13.3% | 17.1% | 0.60 | 3.4% |
| Gold (GLD) | 17.4% | 18.3% | 0.77 | 0.2% |
| Commodities (DBC) | 7.9% | 19.5% | 0.30 | 4.9% |
| Real Estate (VNQ) | 2.8% | 18.9% | 0.05 | 4.2% |
| Bitcoin (BTCUSD) | 9.8% | 54.1% | 0.38 | 1.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCEL | |
|---|---|---|---|---|
| CCEL | -8.6% | 65.0% | -0.01 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 3.1% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 5.4% |
| Gold (GLD) | 11.6% | 16.1% | 0.59 | 0.9% |
| Commodities (DBC) | 5.9% | 18.0% | 0.25 | 5.4% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 6.7% |
| Bitcoin (BTCUSD) | 56.4% | 66.5% | 0.97 | 1.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/17/2024 | 2.5% | 0.2% | 40.2% |
| 2/24/2022 | -0.1% | -1.5% | -6.9% |
| 10/15/2021 | -3.5% | -4.2% | -5.8% |
| 7/19/2021 | 0.0% | 0.0% | 0.0% |
| 4/16/2021 | 0.0% | 0.0% | 0.0% |
| 2/25/2021 | 0.0% | 0.0% | 0.0% |
| 10/19/2020 | 0.0% | 0.0% | 0.0% |
| 7/13/2020 | 0.0% | 0.0% | 0.0% |
| SUMMARY STATS | |||
| # Positive | 6 | 6 | 6 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 0.0% | 0.0% | 0.0% |
| Median Negative | -1.8% | -2.8% | -6.4% |
| Max Positive | 2.5% | 0.2% | 40.2% |
| Max Negative | -3.5% | -4.2% | -6.9% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/17/2024 | 2.5% | 0.2% | 40.2% |
| 2/24/2022 | -0.1% | -1.5% | -6.9% |
| 10/15/2021 | -3.5% | -4.2% | -5.8% |
| 7/19/2021 | 0.0% | 0.0% | 0.0% |
| 4/16/2021 | 0.0% | 0.0% | 0.0% |
| 2/25/2021 | 0.0% | 0.0% | 0.0% |
| 10/19/2020 | 0.0% | 0.0% | 0.0% |
| 7/13/2020 | 0.0% | 0.0% | 0.0% |
| SUMMARY STATS | |||
| # Positive | 6 | 6 | 6 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 0.0% | 0.0% | 0.0% |
| Median Negative | -1.8% | -2.8% | -6.4% |
| Max Positive | 2.5% | 0.2% | 40.2% |
| Max Negative | -3.5% | -4.2% | -6.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 02/28/2026 | 04/14/2026 | 10-Q |
| 11/30/2025 | 02/27/2026 | 10-K |
| 08/31/2025 | 10/15/2025 | 10-Q |
| 05/31/2025 | 07/15/2025 | 10-Q |
| 02/28/2025 | 04/14/2025 | 10-Q |
| 11/30/2024 | 02/28/2025 | 10-K |
| 08/31/2024 | 10/15/2024 | 10-Q |
| 05/31/2024 | 07/15/2024 | 10-Q |
| 02/29/2024 | 04/15/2024 | 10-Q |
| 11/30/2023 | 02/28/2024 | 10-K |
| 08/31/2023 | 10/12/2023 | 10-Q |
| 05/31/2023 | 07/14/2023 | 10-Q |
| 02/28/2023 | 04/21/2023 | 10-Q |
| 11/30/2022 | 02/28/2023 | 10-K |
| 08/31/2022 | 10/18/2022 | 10-Q |
| 05/31/2022 | 07/11/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 02/28/2026 | 04/14/2026 | 10-Q |
| 11/30/2025 | 02/27/2026 | 10-K |
| 08/31/2025 | 10/15/2025 | 10-Q |
| 05/31/2025 | 07/15/2025 | 10-Q |
| 02/28/2025 | 04/14/2025 | 10-Q |
| 11/30/2024 | 02/28/2025 | 10-K |
| 08/31/2024 | 10/15/2024 | 10-Q |
| 05/31/2024 | 07/15/2024 | 10-Q |
| 02/29/2024 | 04/15/2024 | 10-Q |
| 11/30/2023 | 02/28/2024 | 10-K |
| 08/31/2023 | 10/12/2023 | 10-Q |
| 05/31/2023 | 07/14/2023 | 10-Q |
| 02/28/2023 | 04/21/2023 | 10-Q |
| 11/30/2022 | 02/28/2023 | 10-K |
| 08/31/2022 | 10/18/2022 | 10-Q |
| 05/31/2022 | 07/11/2022 | 10-Q |
| 02/28/2022 | 04/13/2022 | 10-Q |
| 11/30/2021 | 02/22/2022 | 10-K |
| 08/31/2021 | 10/15/2021 | 10-Q |
| 05/31/2021 | 07/15/2021 | 10-Q |
| 02/28/2021 | 04/14/2021 | 10-Q |
| 11/30/2020 | 03/01/2021 | 10-K |
| 08/31/2020 | 10/15/2020 | 10-Q |
| 05/31/2020 | 07/10/2020 | 10-Q |
| 02/29/2020 | 04/14/2020 | 10-Q |
| 11/30/2019 | 02/28/2020 | 10-K |
| 08/31/2019 | 10/15/2019 | 10-Q |
| 05/31/2019 | 07/15/2019 | 10-Q |
Insider Activity
Updated 5/29/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Portnoy, David | Chairman, Co-CEO | Direct | Buy | 9182025 | 4.46 | 3,411 | 15,213 | 3,689,954 | Form |
| 2 | Portnoy, David | Chairman, Co-CEO | Corporation | Buy | 9182025 | 4.49 | 1,751 | 7,862 | 726,630 | Form |
| 3 | Portnoy, David | Chairman, Co-CEO | Direct | Buy | 9182025 | 4.43 | 5,564 | 24,649 | 3,650,023 | Form |
| 4 | Portnoy, David | Chairman, Co-CEO | Direct | Buy | 9182025 | 4.46 | 6,449 | 28,763 | 3,649,926 | Form |
| 5 | Portnoy, David | Chairman, Co-CEO | IRA | Buy | 9102025 | 4.40 | 11,035 | 48,554 | 1,183,063 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Portnoy, David | Chairman, Co-CEO | Direct | Buy | 9182025 | 4.46 | 3,411 | 15,213 | 3,689,954 | Form |
| 2 | Portnoy, David | Chairman, Co-CEO | Corporation | Buy | 9182025 | 4.49 | 1,751 | 7,862 | 726,630 | Form |
| 3 | Portnoy, David | Chairman, Co-CEO | Direct | Buy | 9182025 | 4.43 | 5,564 | 24,649 | 3,650,023 | Form |
| 4 | Portnoy, David | Chairman, Co-CEO | Direct | Buy | 9182025 | 4.46 | 6,449 | 28,763 | 3,649,926 | Form |
| 5 | Portnoy, David | Chairman, Co-CEO | IRA | Buy | 9102025 | 4.40 | 11,035 | 48,554 | 1,183,063 | Form |
| 6 | Portnoy, David | Chairman, Co-CEO | Spouse | Buy | 9102025 | 4.47 | 4,817 | 21,532 | 480,091 | Form |
| 7 | Portnoy, David | Chairman, Co-CEO | Direct | Buy | 9102025 | 4.42 | 7,178 | 31,727 | 3,588,686 | Form |
| 8 | Portnoy, David | Chairman, Co-CEO | Corporation | Buy | 9102025 | 4.48 | 9,287 | 41,606 | 717,167 | Form |
| 9 | Portnoy, David | Chairman, Co-CEO | IRA | Buy | 9102025 | 4.49 | 4,815 | 21,619 | 1,157,715 | Form |
| 10 | Portnoy, David | Chairman, Co-CEO | As Custodian for son | Buy | 9102025 | 4.49 | 497 | 2,230 | 51,765 | Form |
| 11 | Portnoy, David | Chairman, Co-CEO | IRA | Buy | 9102025 | 4.31 | 5,271 | 22,718 | 1,090,551 | Form |
| 12 | Portnoy, David | Chairman, Co-CEO | 401K | Buy | 8272025 | 4.42 | 7,860 | 34,741 | 725,684 | Form |
| 13 | Portnoy, David | Chairman, Co-CEO | IRA | Buy | 8272025 | 4.44 | 6,218 | 27,608 | 1,100,041 | Form |
| 14 | Portnoy, David | Chairman, Co-CEO | 401K | Buy | 8272025 | 4.44 | 11,101 | 49,288 | 694,070 | Form |
| 15 | Portnoy, David | Chairman, Co-CEO | 401K | Buy | 8272025 | 4.65 | 9,500 | 44,175 | 675,278 | Form |
| 16 | Portnoy, David | Chairman, Co-CEO | IRA | Buy | 8272025 | 4.53 | 4,500 | 20,385 | 1,094,172 | Form |
| 17 | Portnoy, David | Chairman, Co-CEO | 401K | Buy | 8192025 | 4.37 | 885 | 3,867 | 593,101 | Form |
| 18 | Portnoy, David | Chairman, Co-CEO | 401K | Buy | 8192025 | 4.37 | 9,327 | 40,759 | 589,233 | Form |
| 19 | Portnoy, David | Chairman, Co-CEO | 401K | Buy | 8192025 | 4.50 | 2,671 | 12,020 | 564,790 | Form |
| 20 | Portnoy, David | Chairman, Co-CEO | IRA | Buy | 8192025 | 4.43 | 6,418 | 28,432 | 1,050,083 | Form |
| 21 | Portnoy, David | Chairman, Co-CEO | 401K | Buy | 8182025 | 4.17 | 5,826 | 24,305 | 512,468 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.